Journal

Why the multiple moved.

Deep, source-checked reads on how real companies got re-rated — plus the plain-English terms behind the headlines, for readers just getting started.

A calculator resting on top of tax documents and financial paperwork, representing the tax-preparation software at the center of Intuit's business

$INTUAug 17, 2026

Intuit's Trailing Multiple Collapsed From 73x to 16x as Wall Street Repriced It for AI Disruption

INTU's trailing P/E ran from 66-73x in 2024 to an all-time high near $806, then fell under 16x by mid-2026 as Wall Street repriced TurboTax for AI disruption

SPXScore Team Read the full story

A chrome adjustable wrench resting on a wet workbench surface, representing the tools and hardware at the center of Home Depot's business

$HDAug 15, 2026

Home Depot's Multiple Went From Deep Value to Peak Optimism — Then Did It Again

HD's trailing P/E bottomed near 16.5x in the 2022 rate shock and has since round-tripped through a 2024 M&A-driven re-rating to sit near 25x today, even as trailing earnings shrink. Here's what actually moved the multiple in each phase.

An extreme close-up of a green circuit board with dense silver microchip circuitry, representing the analog and mixed-signal semiconductor components at the center of Analog Devices' business

$ADIAug 13, 2026

Analog Devices' Valuation Signal Went Dark in 2024 — Then the Stock Nearly Doubled Anyway

ADI's trailing P/E tripled from 29x to as high as 78x between January 2024 and mid-2026, but the PEG ratio that's supposed to justify a multiple like that stopped computing in December 2024 and still hasn't come back. Here's what actually happened in each phase.

Stock market charts and graphs displayed on financial screens representing market volatility

#CPIAug 12, 2026

Why Stocks Keep Hitting Records While the Fed Debates a Rate Hike

CPI cooled to 3.4%, PPI held flat, and payrolls missed big — yet the S&P 500 keeps hitting records. How inflation data is shaping Fed policy and stocks in 2026.

Pharmaceutical tablets and capsules representing Johnson & Johnson's prescription drug business

$JNJAug 11, 2026

Johnson & Johnson's Valuation Took a Round Trip Its Earnings Never Made

JNJ traded at under 11x trailing earnings in 2024 and near 30x in 2026. The company didn't change nearly as much as the multiple did — here's what actually happened to Johnson & Johnson's stock, and what it says about pricing it today.